Erik Kinnman
Directeur Général chez VIVESTO AB
Postes actifs de Erik Kinnman
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| STAYBLE THERAPEUTICS AB | Directeur/Membre du Conseil | 01/01/2020 | - |
| ISR IMMUNE SYSTEM REGULATION HOLDING AB (PUBL) | Directeur/Membre du Conseil | 01/01/2022 | - |
| Independent Dir/Board Member | 01/01/2022 | - | |
| VIVESTO AB | Directeur Général | 23/01/2023 | - |
| Kinnman Solutions AB | Président | 01/01/2016 | - |
| Stayble AB | Directeur/Membre du Conseil | - | - |
Historique de carrière de Erik Kinnman
Anciens postes connus de Erik Kinnman
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| SPRINT BIOSCIENCE AB | Directeur Général | 01/03/2021 | 01/01/2023 |
| Investor Relations Contact | - | 01/01/2023 | |
| ABLIVA AB | Directeur Général | 14/03/2016 | 03/02/2021 |
| Public Communications Contact | 14/03/2016 | 03/02/2021 | |
| INFANT BACTERIAL THERAPEUTICS AB | Directeur Technique/Scientifique/R&D | 22/08/2014 | 01/01/2016 |
| SWEDISH ORPHAN BIOVITRUM AB | Corporate Officer/Principal | 01/01/2008 | 01/01/2011 |
| ░░░░░░░░░ ░░ | ░░░░░░ ░░░░░░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░░ ░░░░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | - |
| ░░░░░░ ░░░░ ░░░ ░░░░░░░░ | ░░░░░░░░░░░░░░ | - | - |
| ░░░░░░ ░░░░░░░░░░░░ ░░ | ░░░░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ | - |
Formation de Erik Kinnman
| Karolinska Institutet | Doctorate Degree |
| Stockholm School of Economics | Masters Business Admin |
Statistiques
Internationale
| Suède | 15 |
Opérationnelle
| Chief Executive Officer | 3 |
| Director/Board Member | 3 |
| Public Communications Contact | 2 |
Sectorielle
| Health Technology | 9 |
| Consumer Services | 3 |
| Commercial Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 7 |
|---|---|
| ABLIVA AB | Health Technology |
| VIVESTO AB | Health Technology |
| SWEDISH ORPHAN BIOVITRUM AB | Health Technology |
| EGETIS THERAPEUTICS AB | Health Technology |
| SPRINT BIOSCIENCE AB | Health Technology |
| INFANT BACTERIAL THERAPEUTICS AB | Health Technology |
| STAYBLE THERAPEUTICS AB | Health Technology |
| Entreprise privées | 5 |
|---|---|
Biovitrum AB
 Biovitrum AB Miscellaneous Commercial ServicesCommercial Services Biovitrum AB develops and sells specialist pharmaceuticals that improve people's lives. The company's business goal is to create a pharmaceutical company with long-term profitability through the international launch and sale of in-house developed products. Research expertise and capabilities are focused on development and production of biotechnology therapeutics within the prioritized areas of hemophilia, inflammation/autoimmune diseases, cancer supportive care and malabsorption. The company was founded in January 2001 and is headquartered in Stockholm, Sweden. | Commercial Services |
| Danske Bank A/S (Sweden) | Finance |
| Stayble AB | |
ISR Immune System Regulation Holding AB
 ISR Immune System Regulation Holding AB Pharmaceuticals: MajorHealth Technology ISR Immune System Regulation Holding AB engages in pharmaceutical research for the treatment of viral diseases focusing on Human Immunodeficiency Virus (HIV). It is developing ISR048 for the novel treatment of HIV. The company was founded by Yen Lundgren and Ulf Ljungblad in September 17, 2015 and is headquartered in Solna, Sweden. | Health Technology |
| Kinnman Solutions AB |
- Bourse
- Insiders
- Erik Kinnman
- Expérience
